What are the RFs for progression of Pso to PsA? 🔸PsO disease severity - 3.2x risk —>PsA 🔸Phenotype - nail involvement 🔸Obesity - 6x higher risk of developing PsA 🔸MSK symptoms - arthralgia & heel pain #ACR25 @RheumNow https://t.co/UPXuxBPyKI

• https://x.com/RHEUMarampa/status/1982561742938108050/photo/1
• https://x.com/RHEUMarampa/status/1982561742938108050/photo/1
• https://x.com/RHEUMarampa/status/1982561742938108050/photo/1

The severity of skin psoriasis increases the risk of psoriatic arthritis. Scher J @RheumNow #ACR25 https://t.co/EI0ACWACHy

• https://x.com/synovialjoints/status/1982559833179193832/photo/1

SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease SGLT-2 inhibitors offer benefits beyond glycemic control, such as cardioprotective and nephroprotective effects, and modest weight loss. A recent study also suggests they may have immunomodulatory effects and https://t.co/grsgHFQic5

Is tocilizumab equally effective in ischemic vs. non-ischemic GCA? Ischemic = vision, jaw claudication, or CVA Remission at 6 mo higher in non-ischemic group then with equalization at month 12 No major difference in GCs at month 12 @RheumNow #ACR25 #Abst0739 https://t.co/OeYggSQYx8

• https://x.com/Dr_Brian_MD/status/1982559595559342309/photo/1

RA may age the immune system by nearly two decades. IgG glycome profiles showed inflammatory aging even in early RA, tied to low fitness & high inflammation. Improving muscle & fitness may help reverse this biologic clock. @RheumNow #ACR25 Abstract #0835

We need more biomarkers in GCA - what about fibrinogen? Miller et al retrospectively compared CRP, ESR, and fibrinogen at different points in GCA dx Fibrinogen (and ESR/CRP) only helpful prior to initiation GC with comparable performance @RheumNow #ACR25 Abst #0750 https://t.co/q5gFxDMnTy

• https://x.com/Dr_Brian_MD/status/1982557897369530485/photo/1

Can tissue give us an underlying diagnosis in aortitis? Dr. Kermani breaks down the autoimmune differential based on histopathology @RheumNow #ACR25 https://t.co/twcH021dxS

• https://x.com/Dr_Brian_MD/status/1982556819118776511/photo/1

Abstract 0842 💡 Urinary biomarkers as the next frontier for monitoring lupus nephritis activity 🔹 Proteinuria didn’t track w/ histologic activity 🔹 IL-16 & sCD163 correlated at baseline only 🔹 Urinary Tenascin C & BAFF correlated w/ activity at 1 yr @RheumNow #ACR25

2 year extension data from SELECT-GCA: Patients in remission who remained on upadacitinib 15mg daily after 1 year had 90% reduced risk of flare compared to those who switched to placebo Higher rates zoster, CK elevation in UPA group #ACR25 @RheumNow #ACRBest https://t.co/jf8Dh2wCBj

• https://x.com/Dr_Brian_MD/status/1982552487518413161/photo/1

The differential diagnosis for CNS vasculitis is BROAD. Keep in mind it’s mimics @RheumNow #ACR2025 https://t.co/ASWr6zm5eQ

• https://x.com/MartinezZayasMd/status/1982552066074828985/photo/1

Social media based outreach to pts for research Out of 617,207 users engaged, 6 filled the contact form Based on this social media (knowing also promotion costs) might not be the best strategy to recruit for clinical trials @RheumNow #ACR25 https://t.co/qCH9WXyTD7

• https://twitter.com/drdavidliew/status/1982541142316253359

💊 SGLT2i vs GLP-1 in Lupus Nephritis TriNetX evaluating the impact of GLP-1 agonists vs SGLT-2 inhibitors on outcomes of lupus nephritis 📊 GLP-1 use linked to better renal & CV outcomes in LN including: ⬇️ CKD progression ⬇️ Mortality ⬇️ Acute MI @RheumNow #ACR25 https://t.co/v4LgKFDt68

• https://x.com/AkhilSoodMD/status/1982548790080049436/photo/1

Could a sputum test predict risk for RA conversion in at-risk patients? 98 at risk pts, Converters had higher -BL sputum CCP levels -BL Sputum nucleosome and cit-nucleosome levels !although not asso after adjusting for sputum anti-CCP-IgA level In converters, correlation of https://t.co/bqmQqS1Jz5

• https://x.com/AurelieRheumo/status/1982548110409650512/photo/1
• https://x.com/AurelieRheumo/status/1982548110409650512/photo/1